Friday, March 31, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

FDA Panel Says Yes on Animal Rule for Pneumonic Plague Antibiotic

by Global Biodefense Staff
April 6, 2012

Johnson & Johnson’s antibiotic Levaquin is under consideration by FDA regulators for expanded treatment of pneumonic plague, a potential biological weapon of concern.

Levaquin is already among the stockpile of antibiotics, but federal health authorities are aiming for an expanded approval of Levaquin, to provide faster treatment in plague scenarios of bioterrorism or natural occurring outbreaks.  To accomplish expanded approval, the “Animal Rule” (Code of Federal Regulations 314.610) has been recommended by an advisory panel reviewing the matter this week. The rule allows the FDA to rely on the evidence from studies in animals to provide substantial evidence of effectiveness, where human evaluations are not appropriate for approval.

The panel overwhelmingly agreed that studies performed on monkeys provided substantial evidence of Levaquin’s effectiveness in treating pneumonic plague.  While this recommendation does not mean final acceptance by the FDA, the recommendations are typically followed. A final decision by the agency is expected later this month.

Yersinia pestis (Y. pestis), the causative agent of plague, has several characteristics that make it a significant concern for use as a biological weapon: it can be found in many regions of the world, can be mass-produced, and can be disseminated through direct aerosolization.  The pathogen can be spread through person-to-person contact and therefore has high potential for secondary spreading during an epidemic. Additionally, the pneumonic form of the disease has rapid onset of signs and symptoms and has a very high fatality rate.  All of these characteristics are key factors underlying its classification as a Category A Bioterrorism Agent in the U.S.

Currently, there are no FDA-approved antibacterials specifically indicated for the treatment of pneumonic plague (resulting from the direct inhalation of Y. pestis) for adult or pediatric use.  Neither are there any approved vaccines for plague caused by Y. pestis.   The FDA granted priority review status of the Supplemental New Drug Applications for the pneumonic plague indication to Janssen Research & Development, LLC (a Johnson & Johnson subsidiary) in December 2011.

Tags: AntimicrobialsBioterrorismStrategic National StockpileY. pestis

Related Posts

Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC